Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
Trials ; 24(1): 361, 2023 May 29.
Article in English | MEDLINE | ID: mdl-37248494

ABSTRACT

BACKGROUND: Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code "IB1001-301") for the chronic treatment of symptoms in adult and pediatric patients with NPC. METHODS: This multinational double-blind randomized placebo-controlled crossover phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4 years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments. DISCUSSION: Pre-clinical as well as observational and phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders. TRIAL REGISTRATIONS: The trial (IB1001-301) has been registered at www. CLINICALTRIALS: gov (NCT05163288) and www.clinicaltrialsregister.eu (EudraCT: 2021-005356-10). Registered on 20 December 2021.


Subject(s)
Niemann-Pick Disease, Type C , Humans , Cross-Over Studies , Leucine/therapeutic use , Niemann-Pick Disease, Type C/diagnosis , Niemann-Pick Disease, Type C/drug therapy , Niemann-Pick Disease, Type C/genetics , Quality of Life , Double-Blind Method
2.
Trials ; 22(1): 84, 2021 Jan 22.
Article in English | MEDLINE | ID: mdl-33482890

ABSTRACT

BACKGROUND: The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations and thereby expedite the approval of promising treatments to address patients' high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three separate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 gangliosidoses (Tay-Sachs and Sandhoff disease; "GM2"), and ataxia telangiectasia (A-T). METHODS/DESIGN: The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient's functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the time point of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient's neurological signs and symptoms from video A to video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study and 1-year extension phase. DISCUSSION: The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients' quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases. TRIAL REGISTRATION: The three trials (IB1001-201 for Niemann-Pick disease type C (NPC), IB1001-202 for GM2 gangliosidoses (Tay-Sachs and Sandhoff), IB1001-203 for ataxia telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39), and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).


Subject(s)
Ataxia Telangiectasia , Gangliosidoses, GM2 , Neurodegenerative Diseases , Female , Humans , Leucine , Male , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/drug therapy , Quality of Life
3.
Nat Commun ; 10(1): 4276, 2019 09 19.
Article in English | MEDLINE | ID: mdl-31537798

ABSTRACT

Transport of dietary cholesterol from endocytic organelles to the endoplasmic reticulum (ER) is essential for cholesterol homoeostasis, but the mechanism and regulation of this transport remains poorly defined. Membrane contact sites (MCS), microdomains of close membrane apposition, are gaining attention as important platforms for non-vesicular, inter-organellar communication. Here we investigate the impact of ER-endocytic organelle MCS on cholesterol transport. We report a role for Niemann-Pick type C protein 1 (NPC1) in tethering ER-endocytic organelle MCS where it interacts with the ER-localised sterol transport protein Gramd1b to regulate cholesterol egress. We show that artificially tethering MCS rescues the cholesterol accumulation that characterises NPC1-deficient cells, consistent with direct lysosome to ER cholesterol transport across MCS. Finally, we identify an expanded population of lysosome-mitochondria MCS in cells depleted of NPC1 or Gramd1b that is dependent on the late endosomal sterol-binding protein STARD3, likely underlying the mitochondrial cholesterol accumulation in NPC1-deficient cells.


Subject(s)
Biological Transport/physiology , Cholesterol/metabolism , Endoplasmic Reticulum/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Membrane Proteins/metabolism , Animals , CHO Cells , Carrier Proteins/metabolism , Cell Line, Tumor , Cricetinae , Cricetulus , HeLa Cells , Humans , Intracellular Signaling Peptides and Proteins/genetics , Lysosomes/metabolism , Mitochondria/metabolism , Niemann-Pick C1 Protein , Niemann-Pick Disease, Type C/genetics , RNA Interference , RNA, Small Interfering/genetics
4.
Br J Cancer ; 108(6): 1368-77, 2013 Apr 02.
Article in English | MEDLINE | ID: mdl-23549060

ABSTRACT

BACKGROUND: Necdin (NDN) expression is downregulated in telomerase-immortalised normal human urothelial cells. Telomerase-immortalised normal human urothelial cells have no detected genetic alterations. Accordingly, many of the genes whose expression is altered following immortalisation are those for which epigenetic silencing is reported. METHODS: NDN expression was examined in normal tissues and tumour cell lines by quantitative real-time PCR and immunoblotting. Immunohistochemistry was performed on urothelial carcinoma (UC). Urothelial carcinoma and UC cell lines were subject to HumanMethylation27 BeadChip Array-based methylation analyses. Mutation screening was performed. The functional significance of NDN expression was investigated using retroviral-mediated downregulation or overexpression. RESULTS: NDN protein was widely expressed in normal tissues. Loss of expression was observed in 38 out of 44 (86%) of UC cell lines and 19 out of 25 (76%) of non-UC cell lines. Loss of NDN protein was found in the majority of primary UC. Oncomine analysis demonstrated downregulation of expression in multiple tumour types. In UC, tumour-specific hypermethylation of NDN and key CpG sites where hypermethylation correlated with reduced expression were identified. Six novel mutations, including some of predicted functional significance, were identified in colorectal and ovarian cancer cell lines. Functional studies showed that NDN could suppress colony formation at low cell density and affect anchorage-independent growth and anoikis in vitro. CONCLUSION: NDN is a novel tumour suppressor candidate that is downregulated and hypermethylated or mutated in cancer.


Subject(s)
Biomarkers, Tumor/genetics , DNA Methylation , Genes, Tumor Suppressor , Mutation/genetics , Neoplasms/genetics , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , Cell Proliferation , Cells, Cultured , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Immunoblotting , Immunoenzyme Techniques , Neoplasms/pathology , Nerve Tissue Proteins/metabolism , Nuclear Proteins/metabolism , Promoter Regions, Genetic/genetics , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Urothelium/metabolism
5.
J Neuroimmunol ; 229(1-2): 204-11, 2010 Dec 15.
Article in English | MEDLINE | ID: mdl-20920830

ABSTRACT

X-linked adrenoleukodystrophy (X-ALD) is a severe neurological disease characterized by progressive demyelination within the CNS, adrenal insufficiency, and is associated with an accumulation of saturated very long chain fatty acids in plasma and tissues of patients. iNKT cells, a distinct lineage of T cells recognizing glycolipid antigens through CD1d molecules, exert immunoregulatory functions and can prevent various immune mediated-pathologies. In ALD patients, but not in ALD deficient mice, iNKT cell frequency and CD1d expression on the surface of B cells are slightly decreased. However, such minor differences might not influence the pathogenesis of the disease.


Subject(s)
Adrenoleukodystrophy/pathology , Natural Killer T-Cells/classification , Natural Killer T-Cells/physiology , Adolescent , Adult , Aged , Animals , Antigen-Presenting Cells/physiology , Antigens, CD1/metabolism , Antigens, CD1d/metabolism , Brefeldin A/pharmacology , Child , Cytokines/metabolism , Disease Models, Animal , Flow Cytometry/methods , Glycoproteins/metabolism , Glycosphingolipids/metabolism , Humans , Lipid Metabolism/drug effects , Male , Mice , Mice, Inbred C57BL , Middle Aged , Natural Killer T-Cells/drug effects , Protein Synthesis Inhibitors/pharmacology , Young Adult
6.
Oncogene ; 29(1): 150-5, 2010 Jan 07.
Article in English | MEDLINE | ID: mdl-19802009

ABSTRACT

The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cancer. Recent reports have identified a transforming mutation of AKT1 in breast, colorectal, ovarian and lung cancers. We report here the occurrence of this mutation in bladder tumours. The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours. Cell lines expressing mutant AKT1 show constitutive AKT1 activation under conditions of growth factor withdrawal. We also detected a novel AKT1 mutation G145A (E49K). This mutation also enhances AKT activation and shows transforming activity in NIH3T3 cells, though activity is weaker than that of E17K. Enhanced activation of AKT1 when E17K and E49K mutations are in tandem suggests that they can co-operate.


Subject(s)
Mutation, Missense , Proto-Oncogene Proteins c-akt/genetics , Urinary Bladder Neoplasms/genetics , Animals , Base Sequence , Blotting, Western , Cell Line, Tumor , Cells, Cultured , DNA Mutational Analysis , Enzyme Activation/genetics , Gene Frequency , Humans , Mice , NIH 3T3 Cells , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Serine/metabolism , Threonine/metabolism , Transfection , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/pathology
7.
Pathologe ; 29 Suppl 2: 297-302, 2008 Nov.
Article in German | MEDLINE | ID: mdl-18810447

ABSTRACT

UNLABELLED: The glycosphingolipids globotrihexosylceramide (Gb3, CD77) and isoglobotrihexosylceramide (iGb3) are isomers differing only in one glycosidic bond and have been implicated in several processes of the innate and adaptive immune system. AIMS: 1) To verify the function of Gb3 in the pathogenesis of hemolytic-uremic syndrome as the cellular receptor responsible for cytotoxicity caused by verotoxin (VT) elaborated by Shigella and certain strains of E.coli. 2) To investigate in vivo the previously implicated function of iGb3 as the endogenous lipid ligand responsible for positive selection of invariant natural killer T-cells (iNKT), which have an essential regulatory function in infection, tumor rejection and tolerance. METHODS: Generation of mice deficient in Gb3 and iGb3 synthesizing enzymes and VT injection into Gb3-deficient mice. Analysis of iNKT cell development and function by flow cytometry and by administration of the exogenous agonist alpha-galactosylceramide in iGb3-deficient mice. RESULTS: For 1) Gb3-deficient mice were insensitive to otherwise lethal doses of VT, and 2) iGb3-deficient mice showed normal numbers of iNKT cells. Furthermore the function of iNKT cells evolving in iGb3-deficient mice was unaffected. CONCLUSIONS: 1) Gb3 is the cellular receptor mediating verotoxin cytotoxicity in haemolytic-uremic syndrome. 2) In contrast to previous indirect implications, iGb3 cannot be regarded as an endogenous ligand responsible for the positive selection of iNKT cells.


Subject(s)
Globosides/physiology , Hemolytic-Uremic Syndrome/immunology , Natural Killer T-Cells/immunology , Trihexosylceramides/physiology , Animals , Cytokines/blood , Dendritic Cells/immunology , Escherichia coli/immunology , Female , Globosides/genetics , Lymphocyte Count , Mice , Mice, Knockout , Shiga Toxins/immunology , Shiga Toxins/toxicity , Shigella/immunology , Trihexosylceramides/genetics
8.
Diabetes Obes Metab ; 10(2): 159-66, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18190430

ABSTRACT

AIM: To determine the mechanism of weight loss caused by high doses of N-butyldeoxynojirimycin (NB-DNJ) in healthy lean and leptin-deficient obese (ob/ob) mice. METHODS: Healthy lean and obese mice were treated with NB-DNJ by the following methods: admixed with their diet, delivered by subcutaneously implanted mini-pumps or by intraperitoneal or intracerebroventricular (ICV) injection. Daily changes in body weight and food intake were recorded during the experimental period. The effect of NB-DNJ treatment on subcutaneous adipose tissue and on epididymal fat pads was measured. RESULTS: Lean mice treated with NB-DNJ, admixed with their diet, lost weight in the form of adipose tissue. This resulted in a 40% reduction in skin thickness (control, 358 +/- 11 microm; NB-DNJ treated 203 +/- 6 microm) and a reduction in epididymal fat pad weights after 5 weeks of treatment at 2400 mg/kg/day (control, 0.0154 +/- 0.001; NB-DNJ treated, 0.0026 +/- 0.0005 as ratios of fat pad weight to total body weight). Following the depletion of adipose tissue mass, the mice grew normally and did not have any reduction in lean mass. Obese mice treated with NB-DNJ also lost weight or gained weight at a greatly reduced rate compared with non-treated controls. Body weights at 6 months of age were: lean control, 29.10 +/- 1.15 g; lean NB-DNJ treated, 22.73 +/- 0.29 g; obese control, 63.25 +/- 1.5 g; obese NB-DNJ treated from 5 weeks of age, 35.30 +/- 1.68 g; obese NB-DNJ treated from 12 weeks of age, 38.84 +/- 1.26 g. Both the lean and obese groups of mice treated with NB-DNJ ate up to 30% less than untreated controls. Daily food intake (powder diet) were: lean control, 4.15 +/- 0.54 g; obese control, 4.14 +/- 0.2 g; lean NB-DNJ treated 2.9 +/- 0.37 g; obese NB-DNJ treated, 2.88 +/- 0.47 g. Mice treated with the N-substituted galactose imino sugar analogue, N-butyldeoxygalactonojirimycin (NB-DGJ) did not lose weight. Mice experienced similar weight loss or lack of weight gain when fed a restricted diet that mimics the drug-induced level of food consumption. Delivery of 2 nmol NB-DNJ by ICV injection into lean mice also caused similar reductions in food intake. Food intake: saline vehicle, 4.30 +/- 0.12 g; NB-DNJ, 3.37 +/- 0.19 g; NB-DGJ, 4.03 +/- 0.16 g; 2-deoxyglucose, 4.7 +/- 0.15 g. CONCLUSION: NB-DNJ causes weight loss as a result of reduced food consumption due to central appetite suppression.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Adipose Tissue/drug effects , Appetite Regulation/drug effects , Enzyme Inhibitors/adverse effects , Obesity/metabolism , Weight Loss/drug effects , 1-Deoxynojirimycin/administration & dosage , 1-Deoxynojirimycin/adverse effects , Animals , Leptin/deficiency , Mice , Mice, Obese
9.
Oncogene ; 27(19): 2716-27, 2008 Apr 24.
Article in English | MEDLINE | ID: mdl-18037967

ABSTRACT

E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer. Expression of E2F3 isoforms (E2F3a and b) and CDKAL1 were examined and modulated in 6p22-amplified bladder cell lines. Eight lines with amplification showed overexpression of both E2F3 isoforms and CDKAL1. shRNA-mediated knockdown of CDKAL1 had no effect on proliferation. Knockdown of E2F3a or E2F3b alone induced antiproliferative effects, with the most significant effect on proliferation being observed when both isoforms were knocked down together. As E2Fs interact with the Rb tumour suppressor protein, Rb expression was analysed. There was a striking relationship between 6p22.3 amplification, E2F3 overexpression and lack of Rb expression. This was also examined in primary bladder tumours. Array-CGH detected 6p22.3 amplification in 8/91 invasive tumours. Five were studied in more detail. Four showed 13q14.2 loss (including RB1) and expressed no Rb protein. In the fifth, 13q was unaltered but the CDKN2A locus was deleted. This tumour was negative for p16 and positive for Rb protein. As p16 is a negative regulator of the Rb pathway, its loss represents an alternative mechanism for inactivation. Indeed, a phospho-specific Rb antibody showed much Rb protein in a hyperphosphorylated (inactive) form. We conclude that inactivation of the Rb pathway is required in addition to E2F3 overexpression in this subset of bladder tumours.


Subject(s)
Carcinoma, Transitional Cell/metabolism , Chromosomes, Human, Pair 6/genetics , E2F3 Transcription Factor/genetics , Gene Amplification , Retinoblastoma Protein/antagonists & inhibitors , Signal Transduction , Urinary Bladder Neoplasms/metabolism , Carcinoma, Transitional Cell/genetics , Carcinoma, Transitional Cell/pathology , Cell Line, Transformed , Cell Line, Tumor , Cell Proliferation , Cells, Cultured , Cyclin-Dependent Kinase 5/biosynthesis , Cyclin-Dependent Kinase 5/genetics , E2F3 Transcription Factor/biosynthesis , Gene Expression Regulation, Neoplastic/physiology , Humans , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Retinoblastoma Protein/physiology , Signal Transduction/genetics , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology , tRNA Methyltransferases
10.
Int J Clin Pract ; 61(2): 303-8, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17263717

ABSTRACT

Uncomplicated urinary tract infection (uUTI) is the most common bacterial infection encountered in clinical practice but evaluation and treatment of the illness vary considerably among physicians. The literature suggests that there is often a gap in the perception of symptom severity between physician and patient, a gap that may be a result of the different models they use to explain and manage disease, a result of misinformation or misconceptions about uUTIs, or a result of poor patient-physician communication. This gap in perceptions about uUTI may lead to poor patient care, decreased quality of life and increased antibiotic resistance. Good communication between patient and physician has been shown to result in improved health outcomes. Several approaches to improving communication during consultations have been described in the literature. Physician and patient education and their agreement about any disease, including uUTI can be expected to improve treatment compliance and reduce the incidence of recurrence of such infections. Future work should focus on improvement of communication during clinical consultations to encourage appropriate bidirectional sharing of clinical and patient information. Further research about behavioural risk factors for uUTI may allow evidence-based information to be used in educational programmes.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Physician-Patient Relations , Professional Practice , Urinary Tract Infections/psychology , Adult , Attitude of Health Personnel , Attitude to Health , Female , Humans , Middle Aged , Patient Compliance , Patient Education as Topic , Risk Factors , Secondary Prevention , Severity of Illness Index , Treatment Outcome , Urinary Tract Infections/drug therapy
11.
J Inherit Metab Dis ; 30(1): 79-87, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17189993

ABSTRACT

OBJECTIVE: Fabry disease results from alpha-gala-ctosidase A deficiency and is characterized by the lysosomal accumulation of globotriaosylceramide. Globotriaosylceramide storage predominantly affects endothelial cells, altering vascular wall morphology and vasomotor function. Our objective was to investigate aortic globotriaosylceramide levels, morphology and function in a mouse model of Fabry disease, and the effect of substrate reduction therapy, using the glycosphingolipid biosynthesis inhibitor N-butyldeoxynojirimycin. METHODS AND RESULTS: Mice used were C57BL/6J and alpha-galactosidase A knockout (Fabry). We show progressive accumulation of aortic globotriaosylceramide throughout the lifespan of untreated Fabry mice (55-fold elevation at 2 months increasing to 187-fold by 19 months), localized to endothelial and vascular smooth-muscle cells; there was no effect on vascular wall morphology in young Fabry mice. In old mice, storage resulted in intimal thickening. Endothelial function declined with age in Fabry mouse aorta. Aortae from N-butyldeoxynojirimycin-treated Fabry mice at 19 months of age had reduced endothelial globotriaosylceramide storage, fewer morphological abnormalities and less severe vasomotor dysfunction compared with untreated littermates. CONCLUSION: We provide evidence of a novel vascular phenotype in the Fabry mouse that has relevance to vascular disease in Fabry patients. N-Butyldeoxynojirimycin treatment partially prevented the phenotype in the Fabry mouse by reducing endothelial globotriaosylceramide storage.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Aorta/drug effects , Aorta/pathology , Enzyme Inhibitors/therapeutic use , Fabry Disease/drug therapy , 1-Deoxynojirimycin/therapeutic use , Animals , Aorta/metabolism , Aorta/ultrastructure , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Electron , Phenotype , alpha-Galactosidase/genetics
12.
NMR Biomed ; 18(8): 517-26, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16206131

ABSTRACT

Sandhoff disease, one of several related lysosomal storage disorders, results from the build up of N-acetyl-containing glycosphingolipids in the brain and is caused by mutations in the genes encoding the hexosaminidase beta-subunit. Affected individuals undergo progressive neurodegeneration in response to the glycosphingolipid storage. (1)H magnetic resonance spectra of perchloric acid extracts of Sandhoff mouse brain exhibited several resonances ca 2.07 ppm that were not present in the corresponding spectra from extracts of wild-type mouse brain. High-performance liquid chromatography and mass spectrometry of the Sandhoff extracts post-MRS identified the presence of N-acetylhexosamine-containing oligosaccharides, which are the likely cause of the additional MRS resonances. MRS of intact brain tissue with magic angle spinning also showed additional resonances at ca 2.07 ppm in the Sandhoff case. These resonances appeared to increase with disease progression and probably arise, for the most part, from the stored glycosphingolipids, which are absent in the aqueous extracts. Hence in vivo MRS may be a useful tool for detecting early-stage Sandhoff disease and response to treatment.


Subject(s)
Hexoses/chemistry , Magnetic Resonance Spectroscopy , Sandhoff Disease/metabolism , Animals , Carbohydrate Conformation , Carbohydrate Sequence , Disease Models, Animal , Disease Progression , Humans , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Oligosaccharides/chemistry , Sandhoff Disease/physiopathology , Tissue Extracts/chemistry
13.
J Lipid Res ; 46(4): 744-51, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15687347

ABSTRACT

II3NeuAc-GgOse4Cer (GM1) gangliosidosis is an incurable lysosomal storage disease caused by a deficiency in acid beta-galactosidase (beta-gal), resulting in the accumulation of ganglioside GM1 and its asialo derivative GgOse4Cer (GA1) in the central nervous system, primarily in the brain. In this study, we investigated the effects of N-butyldeoxygalacto-nojirimycin (N B-DGJ), an imino sugar that inhibits ganglioside biosynthesis, in normal C57BL/6J mice and in beta-gal knockout (beta-gal-/-) mice from postnatal day 9 (p-9) to p-15. This is a period of active cerebellar development and central nervous system (CNS) myelinogenesis in the mouse and would be comparable to late-stage embryonic and early neonatal development in humans. N B-DGJ significantly reduced total ganglioside and GM1 content in cerebrum-brainstem (C-BS) and in cerebellum of normal and beta-gal-/- mice. N B-DGJ had no adverse effects on body weight or C-BS/cerebellar weight, water content, or thickness of the external cerebellar granule cell layer. Sphingomyelin was increased in C-BS and cerebellum, but no changes were found for cerebroside (a myelin-enriched glycosphingolipid), neutral phospholipids, or GA1 in the treated mice. Our findings indicate that the effects of N B-DGJ in the postnatal CNS are largely specific to gangliosides and suggest that N B-DGJ may be an effective early intervention therapy for GM1 gangliosidosis and other ganglioside storage disorders.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Brain Stem/metabolism , Cerebellum/metabolism , Gangliosides/metabolism , Gangliosidosis, GM1/metabolism , 1-Deoxynojirimycin/pharmacology , Animals , Animals, Newborn , Cerebellum/drug effects , Cerebellum/pathology , Chromatography, Thin Layer , Mice , Mice, Inbred C57BL , Mice, Knockout , Oxidation-Reduction , Sphingomyelins/metabolism , Substrate Specificity
14.
J Inherit Metab Dis ; 27(6): 757-66, 2004.
Article in English | MEDLINE | ID: mdl-15505381

ABSTRACT

It has been shown that treatment with miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) improves key clinical features of type I Gaucher disease after 1 year of treatment. This study reports longer-term efficacy and safety data. Patients who had completed 12 months of treatment with open-label miglustat (100-300 mg three times daily) were enrolled to continue with therapy in an extension study. Data are presented up to month 36. Liver and spleen volumes measured by CT or MRI were scheduled every 6 months. Biochemical and haematological parameters, including chitotriosidase activity (a sensitive marker of Gaucher disease activity) were monitored every 3 months. Safety data were also collected every 3 months. Eighteen of 22 eligible patients at four centres entered the extension phase and 14 of these completed 36 months of treatment with miglustat. After 36 months, there were statistically significant improvements in all major efficacy endpoints. Liver and spleen organ volumes were reduced by 18% and 30%, respectively. In patients whose haemoglobin value had been below 11.5 g/dl at baseline, mean haemoglobin increased progressively from baseline by 0.55 g/dl at month 12 (NS), 1.28 g/dl at month 24 (p =0.007), and 1.30 g/dl at month 36 (p =0.013). The mean platelet count at month 36 increased from baseline by 22 x 10(9)/L. No new cases of peripheral neuropathy occurred since previously reported. Diarrhoea and weight loss, which were frequently reported during the initial 12-month study, decreased in magnitude and prevalence during the second and third years. Patients treated with miglustat for 3 years show significant improvements in organ volumes and haematological parameters. In conclusion, miglustat was increasingly effective over time and showed acceptable tolerability in patients who continued with treatment for 3 years.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Enzyme Inhibitors/therapeutic use , Gaucher Disease/drug therapy , 1-Deoxynojirimycin/adverse effects , Administration, Oral , Electromyography , Enzyme Inhibitors/adverse effects , Gaucher Disease/pathology , Gaucher Disease/physiopathology , Hemoglobins/metabolism , Hexosaminidases/blood , Humans , Liver/pathology , Magnetic Resonance Imaging , Neural Conduction/physiology , Platelet Count , Spleen/pathology , Tomography, X-Ray Computed
15.
Brain ; 126(Pt 4): 974-87, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12615653

ABSTRACT

Mouse models of the GM2 gangliosidoses [Tay-Sachs, late onset Tay-Sachs (LOTS), Sandhoff] and GM1 gangliosidosis have been studied to determine whether there is a common neuro-inflammatory component to these disorders. During the disease course, we have: (i) examined the expression of a number of inflammatory markers in the CNS, including MHC class II, CD68, CD11b (CR3), 7/4, F4/80, nitrotyrosine, CD4 and CD8; (ii) profiled cytokine production [tumour necrosis factor alpha (TNF alpha), transforming growth factor (TGF beta 1) and interleukin 1 beta (IL1 beta)]; and (iii) studied blood-brain barrier (BBB) integrity. The kinetics of apoptosis and the expression of Fas and TNF-R1 were also assessed. In all symptomatic mouse models, a progressive increase in local microglial activation/expansion and infiltration of inflammatory cells was noted. Altered BBB permeability was evident in Sandhoff and GM1 mice, but absent in LOTS mice. Progressive CNS inflammation coincided with the onset of clinical signs in these mouse models. Substrate reduction therapy in the Sandhoff mouse model slowed the rate of accumulation of glycosphingolipids in the CNS, thus delaying the onset of the inflammatory process and disease pathogenesis. These data suggest that inflammation may play an important role in the pathogenesis of the gangliosidoses.


Subject(s)
Antigens, CD/metabolism , Cytokines/metabolism , Gangliosidoses/etiology , Genes, MHC Class II/physiology , 1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Animals , Apoptosis , Biomarkers/analysis , Blood-Brain Barrier , Enzyme Inhibitors/therapeutic use , Gangliosidoses/drug therapy , Gangliosidoses/pathology , Gangliosidoses, GM2/drug therapy , Gangliosidoses, GM2/etiology , Gangliosidoses, GM2/pathology , Gangliosidosis, GM1/drug therapy , Gangliosidosis, GM1/etiology , Gangliosidosis, GM1/pathology , Immunohistochemistry , Inflammation/pathology , Mice , Sandhoff Disease/drug therapy , Sandhoff Disease/etiology , Sandhoff Disease/pathology , Tay-Sachs Disease/drug therapy , Tay-Sachs Disease/etiology , Tay-Sachs Disease/pathology
16.
Adv Exp Med Biol ; 535: 219-26, 2003.
Article in English | MEDLINE | ID: mdl-14714898

ABSTRACT

Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous. Treatment is often restricted to palliative care, but in some disorders enzyme replacement does offer a significant clinical improvement of disease severity. An alternative therapeutic approach termed "substrate deprivation" or "substrate reduction therapy" (SRT) aims to reduce cellular glycosphingolipid biosynthesis to match the impairment in catalytic activity seen in lysosomal storage disorders. N-Alkylated imino sugars are nitrogen containing polyhydroxylated heterocycles that have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramide-specific glucosyltransferase. The use of N-alkylated imino sugars to establish SRT as an alternative therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been used in clinical trials for type 1 Gaucher disease and has shown to be an effective and safe therapy for this disorder. The results of these trials and the prospects of improvement to the design of imino sugar compounds for treating Gaucher and other glycosphingolipid lysosomal storage disorders will be discussed.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Glycosphingolipids/metabolism , Lysosomal Storage Diseases/drug therapy , 1-Deoxynojirimycin/pharmacology , Animals , Disease Models, Animal , Drug Therapy, Combination , Enzyme Inhibitors/pharmacology , Gaucher Disease/drug therapy , Humans , In Vitro Techniques , Lysosomal Storage Diseases/metabolism , Mice
17.
Neuropathol Appl Neurobiol ; 28(5): 343-57, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12366816

ABSTRACT

Paediatric neurodegenerative diseases are frequently caused by inborn errors in glycosphingolipid (GSL) catabolism and are collectively termed the glycosphingolipidoses. GSL catabolism occurs in the lysosome and a defect in an enzyme involved in GSL degradation leads to the lysosomal storage of its substrate(s). GSLs are abundantly expressed in the central nervous system (CNS) and the disorders frequently have a progressive neurodegenerative course. Our understanding of pathogenesis in these diseases is incomplete and currently few options exist for therapy. In this review we discuss how mouse models of these disorders are providing insights into pathogenesis and also leading to progress in evaluating experimental therapies.


Subject(s)
Glucosylceramides/metabolism , Glycosphingolipids/metabolism , Lysosomal Storage Diseases/etiology , Lysosomal Storage Diseases/therapy , Lysosomes/metabolism , 1-Deoxynojirimycin/administration & dosage , 1-Deoxynojirimycin/analogs & derivatives , Animals , Bone Marrow Transplantation , Chemotherapy, Adjuvant , Disease Models, Animal , G(M2) Ganglioside/metabolism , Gangliosides/metabolism , Glucosyltransferases/antagonists & inhibitors , Glucosyltransferases/metabolism , Humans , Lysosomal Storage Diseases/metabolism , Lysosomal Storage Diseases/pathology , Mice , Models, Biological , Models, Chemical , Morpholines/administration & dosage , Sandhoff Disease/etiology , Sandhoff Disease/metabolism , Sandhoff Disease/pathology , Sandhoff Disease/therapy , Tay-Sachs Disease/etiology , Tay-Sachs Disease/metabolism , Tay-Sachs Disease/pathology , Tay-Sachs Disease/therapy , Treatment Outcome
18.
Anal Biochem ; 298(2): 207-17, 2001 Nov 15.
Article in English | MEDLINE | ID: mdl-11700975

ABSTRACT

The functional importance of glycolipids has emphasized the need for more sensitive methods of detection, characterization, and quantification than has often been possible using traditional thin-layer chromatographic techniques. We describe the use of ceramide glycanase and HPLC to identify and quantify gangliosides in which the carbohydrate is in Glcbeta1--> linkage with ceramide. Detection of released carbohydrate was by fluorescent labeling with 2-aminobenzamide at the reducing terminal prior to HPLC analysis. Under the conditions described, ceramide glycanase hydrolyzed all of the common gangliosides studied, offering a broad spectrum of specificity. Release and detection of carbohydrate were linear over a wide range (over two orders of magnitude) of micromolar glycolipid substrate concentrations. Use of an N-linked glycan as an internal standard allowed accurate quantification and a recovery of 93% was achieved. The method additionally maintained the sensitivity (chromatographic peaks containing 1 pmol were readily detected from tissue samples) and comparable resolution to related assays. This was shown by the separation, not only of isomeric carbohydrates from the "a" and "b" series, but also of ganglioside carbohydrate differing only by the presence of either N-acetyl- or N-glycolylneuraminic acid. Application of the method to neutral glycosphingolipids and to tissue samples, including 10-microl quantities of plasma, is illustrated. Glycan structures were confirmed by exoglycosidase digestion and/or matrix-assisted laser desorption/ionization mass spectrometry.


Subject(s)
Chromatography, High Pressure Liquid/methods , Fluorescent Dyes , Glycoside Hydrolases/metabolism , Oligosaccharides/chemistry , ortho-Aminobenzoates , Aminopyridines , Animals , CHO Cells , Carbohydrate Sequence , Chromatography, Thin Layer , Cricetinae , Female , Glycolipids/blood , Glycosphingolipids/metabolism , Humans , Liver/metabolism , Mice , Molecular Sequence Data , Oligosaccharides/isolation & purification , Sarcoma/metabolism , Sensitivity and Specificity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Uterine Neoplasms/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...